NCT05621551CompletedPhase 4
Dapagliflozin Therapy In Cardiac Surgery
Effects of Perioperative Dapagliflozin on Type 2 Diabetic Patients Undergoing Cardiac Surgery
Source: ClinicalTrials.gov · Last updated 15 Jul 2025
Brief summary (registry, in English)
This randomized controlled trial is to assess the effects of perioperative dapagliflozin on type 2 diabetic patients undergoing cardiac surgery
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 178 (actual)
- First submitted
- 4 Nov 2022
- Start date
- 11 Nov 2022
- Primary completion date
- 1 Jun 2024
- Lead sponsor
- China National Center for Cardiovascular Diseases
- Diseases
- Type 2 diabetes
- NCT number
- NCT05621551
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 178
- From 11 Nov 2022 to the primary completion date, 1 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Emergency surgery and non-primary surgery
- Receiving therapy with an SGLT2 inhibitor within 4 weeks prior to enrolment
- Currently enrolled in another investigational drug study, or less than 30 days
Other illness
- History of diabetic ketoacidosis; type 1 diabetes mellitus
- Known allergy or hypersensitivity to dapagliflozin or other SGLT-2 inhibitors
- Serious hepatic disease
Lab values
- Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m2 or requiring dialysis; unstable or rapidly progressing renal disease at the time of randomisation
Other
- Moderate and severe dehydration; systolic pressure≤90mmHg; unstable haemodynamics
- Women who are pregnant, nursing, or who plan to become pregnant while in the trial
Who the study is looking for
- Age ≥ 18 years at screening
- Scheduled for cardiac surgery (on-pump coronary artery bypass grafting, aortic valve replacement, or a combination of both)
- Diagnosis of Type 2 Diabetes
- Provision of signed informed consent prior to any study specific procedures
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.